Update

Dear fellow Shareholders,

By now, you should have all received our first correspondence by post. This letter has been sent to every one of the more than 5000 CST shareholders on the official shareholder register.

The response to the letter has been astounding. Many shareholders, both large and small, have subsequently contacted us. A regular comment is that shareholders had decided independently that they are opposed to the takeover but thought they were alone and that, in the end, they would have no choice. They have expressed their pleasure in finding that there is a solid group of like minded shareholders that will prevent this offer of a takeover at $3.55 from proceeding.

We offer a huge welcome to all those shareholders who have recently registered with us. You can catch up with the story so far at www.csag-blog.com. We particularly draw your attention to the Cellestis Research Report and our DCF Valuation available on the website. Those two documents alone clearly support the case for voting NO to this opportunistic offer.

Major new information is coming to light daily confirming the pace of the uptake of QuantiFERON. A great place to keep an eye on this is www.quantiferon.blogspot.com

To date we have received expressions of an intention to vote NO from shareholders representing 38% of the shareholding of Cellestis.

The CSAG Team continues to work incessantly on defeating this takeover offer. It is the ongoing support of the shareholders that makes this a worthwhile task.

Whilst we will continue to keep shareholders informed on any salient events, our next major task will be a reply to the Scheme Documents when they are released by Cellestis.

We repeat our previous suggestion that all shareholders should refrain from voting for the Scheme until they have received our reply. It will be sent by post to every shareholder as soon as possible after the Scheme documents have been released. We will ensure that you will have ample time to successfully lodge your vote.

The CSAG Team.